Fortress Biotech Inc. (FBIO)
Fortress Biotech Inc. (FBIO) Stock Price, Analysis & Data
| Bid | 1.88 |
| Market Cap | 88.36M |
| Revenue (ttm) | 66.16M |
| Net Income (ttm) | 119.2M |
| Beta | 1.21 |
| EPS (ttm) | 3.23 |
| PE Ratio (ttm) | 0.82 |
| Forward PE | -1.51 |
| P/B (ttm) | 0.54 |
| P/S (ttm) | 1.34 |
| Earnings Date | Aug 13, 2025 |
| Ask | 3.31 |
| Volume | 224,604 |
| Avg. Volume (20D) | 579,204 |
| Open | 2.61 |
| Previous Close | 2.61 |
| Day's Range | 2.57 - 2.66 |
| 52-Week Range | 1.90 - 4.53 |
| Analyst | n/a |
| Price Target | 11 (313.53%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About FBIO
Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne; Amzeeq, a minocycline topical ...
Financial Performance
In 2025, Fortress Biotech's revenue was 63.26M, an increase of 9.69% compared to the previous year's 57.67M. Earnings were 6.82M, a decrease of -114.82%.
Financial StatementsAnalyst Forecast
According to 2 analyst ratings, the average rating for FBIO stock is "null". The 12-month stock price forecast is 11, which is upside of 313.53% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
